Nucleic acids encoding anti-C5a antibodies
First Claim
Patent Images
1. An isolated nucleic acid comprising a nucleotide sequence encoding an antibody, or antigen binding fragment thereof, wherein the antibody, or antigen binding fragment thereof, comprises:
- (a) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
140;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
96;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
142;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
144; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
117;
(b) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21; and
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
67; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
30;
(c) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
156;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
157;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
158;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
160;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
161; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
162;
(d) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
164;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
165;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
166;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
168;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
169; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
170;
(e) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
172;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
173;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
174;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
176;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
177; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
178;
(f) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
84;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
85;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
86;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
116; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
117;
(g) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
88;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
89;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
90;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
119;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
120; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
121;
(h) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
99;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
100;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
101;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
119;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
126; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
127;
(i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
113;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47;
(j) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
110;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
111;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
136;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
137; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
138;
(k) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
105;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
106;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
107;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
124; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
117;
(l) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
29; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
30;
(m) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
38;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
29; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
30;
(n) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47;
or(o) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
38;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47.
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospholipid syndrome, asthma, lupus nephritis, Goodpasture'"'"'s syndrome, and chronic obstructive pulmonary disease.
-
Citations
20 Claims
-
1. An isolated nucleic acid comprising a nucleotide sequence encoding an antibody, or antigen binding fragment thereof, wherein the antibody, or antigen binding fragment thereof, comprises:
-
(a) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
140;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
96;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
142;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
144; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
117;(b) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21; and
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
67; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
30;(c) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
156;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
157;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
158;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
160;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
161; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
162;(d) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
164;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
165;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
166;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
168;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
169; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
170;(e) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
172;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
173;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
174;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
176;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
177; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
178;(f) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
84;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
85;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
86;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
116; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
117;(g) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
88;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
89;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
90;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
119;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
120; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
121;(h) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
99;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
100;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
101;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
119;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
126; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
127;(i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
113;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47;(j) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
110;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
111;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
136;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
137; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
138;(k) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
105;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
106;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
107;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
124; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
117;(l) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
29; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
30;(m) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
38;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
29; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
30;(n) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47;
or(o) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
38;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47. - View Dependent Claims (2, 13, 14)
-
-
3. An isolated nucleic acid comprising a nucleotide sequence encoding a polypeptide, wherein the polypeptide comprises the amino acid sequence depicted in SEQ ID NO:
- 17, SEQ ID NO;
25, SEQ ID NO;
33, SEQ ID NO;
36, SEQ ID NO;
40, SEQ ID NO;
44, or SEQ ID NO;
49. - View Dependent Claims (4, 5, 15, 16)
- 17, SEQ ID NO;
-
6. An isolated nucleic acid comprising a nucleotide sequence encoding an antibody variable region, wherein the antibody variable region is at least 90% identical to the amino acid sequence depicted in SEQ ID NO:
- 19, SEQ ID NO;
27, SEQ ID NO;
37, SEQ ID NO;
42, or SEQ ID NO;
45. - View Dependent Claims (7, 8, 17, 18)
- 19, SEQ ID NO;
-
9. An isolated nucleic acid comprising a nucleotide sequence encoding an antibody variable region, wherein the antibody variable region comprises the amino acid sequence depicted in SEQ ID NO:
- 19, SEQ ID NO;
27, SEQ ID NO;
37, SEQ ID NO;
42, or SEQ ID NO;
45. - View Dependent Claims (10, 11, 19, 20)
- 19, SEQ ID NO;
-
12. An isolated nucleic acid comprising a nucleotide sequence encoding an antibody, or antigen binding fragment thereof, wherein the antibody, or antigen binding fragment thereof, comprises a light chain variable region comprising the amino acid sequence depicted in SEQ ID NO:
- 42 and a heavy chain variable region comprising the amino acid sequence depicted in SEQ ID NO;
45.
- 42 and a heavy chain variable region comprising the amino acid sequence depicted in SEQ ID NO;
Specification